Developing Novel Therapies For Pediatric And Young Adult Acute Lymphoblastic Leukemia (ALL)

The cure rate for childhood acute lymphoblastic leukemia (ALL), the most common pediatric cancer has risen dramatically over the past four decades. Despite this, major challenges still exist and ALL remains the most common cause of cancer death in children.

In October, 2013, Dr. William L. Carroll was awarded a Leukemia & Lymphoma Society Specialized Center of Research (SCOR) that supports multicenter research with the potential to improve the treatment of ALL in young patients. The SCOR is a 5-year, $6.25 million award and is the culmination of decades of work by a group of highly collaborative, multi-institutional investigators with a strong track record of moving laboratory findings into the clinic. It is composed of four projects and two cores.

We encourage you to explore this SCOR’s website for additional information on specific projects and cores, as well as updates on progress!

Principal Investigator

William L. Carroll, MD
The Julie & Edward J. Minskoff Professor of Pediatrics
Professor of Pathology
Director, Perlmutter Cancer Center

 

Press Releases

October 4, 2013  -  NYU Cancer Institute Leads $6.25 Million Research Effort to Find New Therapies for the Most Common Form of Childhood Cancer

 

Sponsors and Contributors

We would like to thank our sponsor, the Leukemia & Lymphoma Society (LLS), without whose support, this research would not be possible. We encourage you to visit their website for more information about the organization.

Additional support for the SCOR is provided by the St. Baldrick’s Foundation. We thank them for their commitment to help fight childhood cancer and encourage you to visit their website for more information about the organization.